Thank you for joining

The presentation will begin shortly
Expanding and Extending the RIZE Campaign
Stephen Shields, MPH, AMGA Research and Analytics
April 18, 2024
Today’s Webinar

Campaign Updates
• Campaign Spotlight: Hepatitis B Foundation
• AC24 highlights
• Expansion/ Extension Overview

Expanding and Extending the RIZE Campaign
• Stephen Shields, MPH, AMGA Research and Analytics

Q&A Session
Webinar Reminders

Today’s webinar recording will be available the week of 04/22
- Will be sent via email
- Will be available on website

(RiseToImmunize.org → “Resources” → “Webinars”)

Ask questions during the webinar using the Q&A feature
- Questions will be answered at the end of the presentation
Campaign Spotlight
AC24 Highlights

“While we are proud of the innovation reflected in our new vaccine, we are not complacent. We continue to be committed to a relentless pursuit of scientific innovation.”

- Andrew Martin, MBA, US Vaccines Lead, Pfizer, Inc. at the AMGA Foundation Celebration
More Vaccines!

- Influenza
- Pneumococcal
- Td/Tdap
- Zoster

+ 

- RSV
- COVID-19
- Hepatitis B
More Time!

The RIZE campaign will be extended through 2027
Through the RIZE campaign, you can:

- Continue to tackle immunization barriers and inequities.
- Focus on additional vaccines of your choosing.
- Hardwire changes for sustainability.
Together we can administer **30 million vaccines** by **2027** through comprehensive & equitable vaccine initiatives.
How to add new measures:

Use the QR code to access the Measure Upgrade Form

Or email RiseToImmunize@amga.org and we can assist you!
Thank you to all of our sponsors who have committed to the expansion and extension!
Stephen Shields, MPH, Lead Population Health Research Analyst, AMGA Research and Analytics
Extending and Expanding RIZE!

April 18th, 2024
Agenda

• Overview
• Expansion Measure Details
• Timeline
• What’s next? 😊
Why Measures?

Essential to any improvement process

Gauge impact of interventions

Learn from peers via benchmarking

Inspire change within organizations
Extension and Expansion
Extension and Expansion

- **Extension** = the campaign will run through 2027
  - Data reports through Q2 2027, but campaign will run through Q4 2027
- **Expansion** = addition of 3 new measures
  - Age-based CDC recommendations

<table>
<thead>
<tr>
<th>Measures</th>
<th>Age Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>RSV*</td>
<td>60+</td>
</tr>
<tr>
<td>COVID-19</td>
<td>19+</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>19-59</td>
</tr>
</tbody>
</table>

*respiratory syncytial virus
Extension and Expansion

• Basic and Core tracks will remain the same
  o Bundle measure will remain unchanged

• Each extension measure will be an optional add-on
  o One year of baseline data, Measurement Year ‘23 (Q3 2023 – Q2 2024)

• Update Measure Specifications (v2.0) are available on the Rise to Immunize® website

• A separate Expansion Measures Value Set will be sent via email in summer 2024
## Campaign Measures

<table>
<thead>
<tr>
<th>Measures</th>
<th>Age Group</th>
<th>Basic Track</th>
<th>Core Track</th>
</tr>
</thead>
<tbody>
<tr>
<td>Influenza</td>
<td>19+</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Pneumococcal</td>
<td>66+</td>
<td>✓</td>
<td>✓</td>
</tr>
<tr>
<td>Td/Tdap</td>
<td>19+</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Zoster</td>
<td>50+</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>Bundle</td>
<td>66+</td>
<td></td>
<td>✓</td>
</tr>
<tr>
<td>RSV</td>
<td>60+</td>
<td>Optional</td>
<td>Optional</td>
</tr>
<tr>
<td>COVID-19</td>
<td>19+</td>
<td>Optional</td>
<td>Optional</td>
</tr>
<tr>
<td>Hepatitis B</td>
<td>19-59</td>
<td>Optional</td>
<td>Optional</td>
</tr>
</tbody>
</table>
Reminder: 
Active Patient Population
Active Patient Lookback Period (APL)

- Spans from 15 months prior to Q3 of each MY to the end of the Current Measurement Period (MP)
  - Resets at the beginning of each MY (Q3)
- Patients with specified activity *in the Active Patient Lookback Period (APL)* will be included

<table>
<thead>
<tr>
<th>Reporting Quarter (RQ)</th>
<th>Quarters Included in Active Patient Lookback (APL)</th>
<th># of Months in APL</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q3</td>
<td>Q2  Q3  Q4  Q1  Q2  Q3</td>
<td>18</td>
</tr>
<tr>
<td>Q4</td>
<td>Q2  Q3  Q4  Q1  Q2  Q3  Q4</td>
<td>21</td>
</tr>
<tr>
<td>Q1</td>
<td>Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1</td>
<td>24</td>
</tr>
<tr>
<td>Q2</td>
<td>Q2  Q3  Q4  Q1  Q2  Q3  Q4  Q1  Q2</td>
<td>27</td>
</tr>
</tbody>
</table>
**Active Patient Population**

**Inclusion**
1. Age 19–99 on the first day of the Measurement Year (MY) (July 1st),  
   AND
2. Completed ≥1 ambulatory visit in the APL with any specialty  
   AND
3. have EITHER  
   • an Assigned PCP,  
     OR  
   • ≥1 ambulatory visit with a PCP in the APL.

**Exclusion**
1. Evidence of hospice or palliative care in the APL,  
   OR
2. Death prior to the end of the RQ.

Per NAC recommendations, not all exclusions in the HEDIS® AIS measure (e.g., history of immunocompromising conditions) are used in Rise to Immunize™.

For Organizations that elect to use the Assigned PCP designation, patients meeting EITHER criterion (Assigned PCP OR ≥1 visit with a PCP) should be considered eligible for the APL.

If Assigned PCP is not a reliable designation at your organization, individual HCOs can elect to only use ≥1 visit with a PCP in the APL.
Expansion Measure Details
Proportion of patients who ever received the RSV vaccination*

Denominator
- All patients aged 60+

Numerator Part A
- Patients who received RSV vaccine during the Measurement Year

Numerator Part B
- Patients who received RSV vaccine prior to the Measurement Year or had an adverse reaction caused by the RSV vaccine

*subject to change per upcoming ACIP recommendation (e.g., every 2 years)
RSV

Active Patient Population

Age 60 or older on the first day of the Measurement Year

No → Exclude

Yes → Measure 7 Denominator

Received an RSV vaccination in the MP\textsuperscript{1,2} (at the HCO or elsewhere)

No → Received an RSV vaccination prior to the MP\textsuperscript{1,2}

No → Ever had an adverse reaction to an RSV vaccination

No → Not Numerator Compliant

Yes → Numerator Part A

Yes → Numerator Part B
COVID-19

Proportion of patients who received the COVID-19 vaccination in the Measurement Year*

Denominator

• All patients aged 19+

Numerator

• Patients who received one COVID-19 vaccination during the Measurement Year or had an adverse reaction to a COVID-19 vaccine

*subject to change per upcoming ACIP recommendation
COVID-19

Active Patient Population

Measure 8 Denominator

Received a COVID-19 vaccination (at the HCO or elsewhere) during the MP

Has a history of adverse reaction to a COVID-19 vaccine

No

Yes

Not Numerator Compliant

Measure 8 Numerator
Hepatitis B

Proportion of patients who completed the Hepatitis B series during or prior to the Measurement Year

Denominator

• All patients aged 19-59

Numerator Part A

• Patients that completed the series during the Measurement Year

Numerator Part B

• Patients that completed the series prior to the Measurement Year
Hepatitis B

Active Patient Population

Age 19-59 on the first day of the Measurement Year

No → Exclude

Yes → Measure 6 Denominator

Completed the hepatitis B vaccination series in the MP\textsuperscript{1,2} (at the HCO or elsewhere)

No → Numerator Part A

Yes → Completed the hepatitis B vaccination series prior to the MP\textsuperscript{2}

No → Ever had an adverse reaction to a hepatitis B vaccination

No → Not Numerator Compliant

Yes → Numerator Part B

Yes
Documentation and Administration

HCOs should ultimately use their OWN definitions and policies of vaccination documentation

- Influenza, COVID-19: Recommend accepting credible patient self-reports
- Pneumo., Tdap, Zoster, RSV, Hep B: Recommend requiring documentation stating that the vaccination was administered
Value Sets and Data Sources

- An Expansion Value Set will be sent via email
- Data elements can be derived from
  - medical and pharmacy claims and records
  - (electronic) practice management systems (PM or EPM)
  - electronic health record systems (EHR)
  - health maintenance tables
  - disease registries
  - population health software
  - local/state/regional vaccine registries
  - other health records, etc.
- Recorded or collected directly at point-of-care, or from another data source
Expansion and Extension Reporting Timelines
Reporting Timelines for Expansion Measures

The first Expansion Measure Reporting Quarter is Q3 2024, therefore...

... the first report with the additional expansion measures is due on October 15th, 2024

This report should include the previous Measurement Year (MY 2023) as Baseline
# Reporting Timelines for Expansion Measures

<table>
<thead>
<tr>
<th>Flu Season (Measurement Year)</th>
<th>Reporting Quarter</th>
<th>Report Due Date</th>
<th>BCR Provided</th>
</tr>
</thead>
<tbody>
<tr>
<td>2023</td>
<td>Q3 2023</td>
<td>Oct 16, 2023</td>
<td>Nov 29, 2023</td>
</tr>
<tr>
<td></td>
<td>Q4 2023</td>
<td>Jan 16, 2024</td>
<td>Feb 27, 2024</td>
</tr>
<tr>
<td></td>
<td>Q1 2024</td>
<td>Apr 15, 2024</td>
<td>May 29, 2024</td>
</tr>
<tr>
<td></td>
<td>Q2 2024</td>
<td>Jul 15, 2024</td>
<td>Aug 26, 2024</td>
</tr>
<tr>
<td>2024</td>
<td>Q3 2024</td>
<td>Oct 15, 2024</td>
<td>Nov 26, 2024</td>
</tr>
<tr>
<td></td>
<td>Q4 2024</td>
<td>Jan 15, 2025</td>
<td>Feb 26, 2025</td>
</tr>
<tr>
<td></td>
<td>Q1 2025</td>
<td>Apr 15, 2025</td>
<td>May 28, 2025</td>
</tr>
<tr>
<td></td>
<td>Q2 2025</td>
<td>Jul 15, 2025</td>
<td>Aug 26, 2025</td>
</tr>
<tr>
<td>2025</td>
<td>Q3 2025</td>
<td>Oct 15, 2025</td>
<td>Nov 19, 2025</td>
</tr>
<tr>
<td></td>
<td>Q4 2025</td>
<td>Jan 15, 2026</td>
<td>Feb 19, 2026</td>
</tr>
<tr>
<td></td>
<td>Q1 2026</td>
<td>Apr 15, 2026</td>
<td>May 21, 2026</td>
</tr>
<tr>
<td></td>
<td>Q2 2026</td>
<td>Jul 15, 2026</td>
<td>Aug 19, 2026</td>
</tr>
<tr>
<td>2026</td>
<td>Q3 2026</td>
<td>Oct 15, 2026</td>
<td>Nov 19, 2026</td>
</tr>
<tr>
<td></td>
<td>Q4 2026</td>
<td>Jan 15, 2027</td>
<td>Feb 19, 2027</td>
</tr>
<tr>
<td></td>
<td>Q1 2027</td>
<td>Apr 15, 2027</td>
<td>May 14, 2027</td>
</tr>
<tr>
<td></td>
<td>Q2 2027</td>
<td>Jul 15, 2027</td>
<td>Aug 19, 2027</td>
</tr>
</tbody>
</table>
Reporting Process

• Reporting process will remain the same
• Send your Reporting Template to DataforRize@amga.org each quarter
What’s next?
What’s next?

• An updated reporting template with added extension years and expansion measures (also this summer)

And …
Introducing the RIZE dashboard

A new way to view RIZE data!

Preview: WIP
RIZE Dashboard

• All features from the previous pdf reports will be available in the dashboard
• Dashboard will streamline reporting, allow highlighting of your group
  o Exploring stratifications- see how you compare to organizations of similar size!
• Dashboard will be accessible from the RIZE website, like how previous reports were accessed
• Backend data remains on AMGA-owned servers
Add the campaign email to your safe sender list

RiseToImmunize@amga.org

If you need assistance setting up measures or have any questions, please email us! We’d be happy to set up a meeting.
Questions
Upcoming Webinar

**Topic:** Making Respiratory Health a Priority: Insights for Health Care Professionals

**Date/ Time:** Thursday, May 16 at 2pm ET

**Presenter:** Carrie Regnier, BS, BSN, MPH, RN, *AMGA National Advisor*
Questions?

Submit your questions using the **Q&A feature** at the bottom of the screen.